A. Pierce

发表

Leber's hereditary optic neuropathy in the setting of nucleoside analogue toxicity.

J. Hoy, A. Hall, J. Luzhansky, 2001, AIDS.

Adherence to HIV Treatment Guidelines for Comorbid Disease Assessment and Initiation of Antiretroviral Therapy

M. Bailey, M. Bloch, J. Hoy, 2012, Journal of acquired immune deficiency syndromes.

Is the recommendation for pneumococcal vaccination of HIV patients evidence based?

J. Hoy, A. Pierce, Anna B. Pierce, 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Developing an evidence‐based guideline for the management of exposure to hepatitis B at a Victorian tertiary hospital

A. Pierce, J. Armishaw, S. Aitchison, 2013, Australian and New Zealand journal of public health.

Managing the patient on antiretroviral therapy

O. Vujovic, A. Pierce, 2009 .

Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial

M. Kainer, A. Peleg, J. Trubiano, 2022, eClinicalMedicine.

Routine vaccinations for HIV-1 infected adults

S. Kent, A. Pierce, 2001 .

Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.

S. Lewin, D. Cooper, D. Smit, 2013, The Journal of infectious diseases.

Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.

A. McNulty, A. Carr, T. Read, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir with tenofovir disoproxil fumarate–emtricitabine as HIV postexposure prophylaxis in gay and bisexual men

A. McNulty, A. Carr, J. Mcallister, 2017, AIDS.

Antiretroviral therapy 5

A. Pierce, 2003 .

Rates of combination antiretroviral treatment change in Australia, 1997–2000

C. Moore, S. Mallal, D. Cooper, 2002 .

Near Death Experience Cells Escaping a Non-MHC Gene-Controlled Enhanced Pathogenicity of Diabetogenic

C. Choisy-Rossi, D. Serreze, H. Chapman, 2004 .

Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study

Christina C. Chang, R. Grant, J. D. de Wit, 2018, Front. Public Health.

Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system.

M. Stoové, J. Hoy, C. El-Hayek, 2016, Sexual health.

Non-occupational post-exposure prophylaxis in Victoria, Australia: responding to high rates of re-presentation and low rates of follow-up

Brian L. Price, J. Hoy, E. Wright, 2011, International journal of STD & AIDS.

HIV seroconversions among male non-occupational post-exposure prophylaxis service users: a data linkage study.

R. Guy, M. Stoové, J. Hoy, 2011, Sexual health.

Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus

D. Mackey, N. Howell, P. McCluskey, 2003, Eye.

Anna Pierce 10 . 1 Therapeutic drug monitoring Interest in therapeutic drug monitoring ( TDM ) as an adjunct in the management of

A. Pierce, 2003 .

Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient

Z. McQuilten, J. Druce, M. Catton, 2021, Infection Control & Hospital Epidemiology.

Nonoccupational post‐exposure prophylaxis source tracing: is it really feasible in Australia?

Brian L. Price, C. Fairley, J. Hoy, 2012, HIV medicine.

Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.

S. Lewin, D. Cooper, D. Smit, 2013, The Journal of infectious diseases.